Seyger MM - Search Results

1

Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for psoriatic lesions.

Seyger MM, van Pelt JP, van den Born J, Latijnhouwers MA, de Jong EM. Seyger MM, et al. Arch Dermatol Res. 1997 May;289(6):331-6. doi: 10.1007/s004030050200. Arch Dermatol Res. 1997. PMID: 9209678 Free article.

2

Altered distribution of heparan sulfate proteoglycans in psoriasis.

Seyger MM, van den Born J, Schalkwijk J, van de Kerkhof PC, de Jong EM. Seyger MM, et al. Acta Derm Venereol. 1997 Mar;77(2):105-9. doi: 10.2340/0001555577105109. Acta Derm Venereol. 1997. PMID: 9111818 Free article. Clinical Trial.

3

Reliability of two methods to assess morphea: skin scoring and the use of a durometer.

Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Seyger MM, et al. J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):793-6. doi: 10.1016/s0190-9622(97)70121-x. J Am Acad Dermatol. 1997. PMID: 9366834 Free article. Clinical Trial. No abstract available.

4

Low-dose methotrexate in the treatment of widespread morphea.

Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Seyger MM, et al. J Am Acad Dermatol. 1998 Aug;39(2 Pt 1):220-5. doi: 10.1016/s0190-9622(98)70079-9. J Am Acad Dermatol. 1998. PMID: 9704833 Clinical Trial.

5

The efficacy of a new topical treatment for psoriasis: Mirak.

Seyger MM, van de Kerkhof PC, van Vlijmen-Willems IM, de Bakker ES, Zwiers F, de Jong EM. Seyger MM, et al. J Eur Acad Dermatol Venereol. 1998 Jul;11(1):13-8. J Eur Acad Dermatol Venereol. 1998. PMID: 9731960 Clinical Trial.

6

Decreased staining of heparan sulfate in non-lesional skin of a subgroup of patients with systemic lupus erythematosus.

Seyger MM, van Bruggen MC, Hardeman HK, van den Hoogen FH, Berden JH, van den Born J, De Jong EM. Seyger MM, et al. Acta Derm Venereol. 1998 Sep;78(5):326-30. doi: 10.1080/000155598442971. Acta Derm Venereol. 1998. PMID: 9779246 Free article.

7

A patient with a severe scleroedema diabeticorum, partially responding to low-dose methotrexate.

Seyger MM, van den Hoogen FH, de Mare S, van Haelst U, de Jong EM. Seyger MM, et al. Dermatology. 1999;198(2):177-9. doi: 10.1159/000018103. Dermatology. 1999. PMID: 10325473 No abstract available.

8

Localized and systemic scleroderma show different histological responses to methotrexate therapy.

Seyger MM, van den Hoogen FH, van Vlijmen-Willems IM, van de Kerkhof PC, de Jong EM. Seyger MM, et al. J Pathol. 2001 Apr;193(4):511-6. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH779>3.0.CO;2-8. J Pathol. 2001. PMID: 11276011

9

Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE.

Otero ME, van den Reek JM, Seyger MM, van de Kerkhof PC, Kievit W, de Jong EM. Otero ME, et al. Among authors: seyger mm. Br J Dermatol. 2017 Aug;177(2):497-504. doi: 10.1111/bjd.15305. Epub 2017 May 11. Br J Dermatol. 2017. PMID: 28078672

10

The dynamics of endothelial changes in vivo following standardized skin injury.

Hanssen SCA, Keijsers RRMC, Hendriks AGM, Seyger MMB, van der Vleuten CJM, van de Kerkhof PCM. Hanssen SCA, et al. Skin Res Technol. 2019 Sep;25(5):618-624. doi: 10.1111/srt.12693. Epub 2019 Apr 3. Skin Res Technol. 2019. PMID: 30942508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters